Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, reported a significant decline in revenue for the fiscal year ending December 31, 2025, with total revenues of $3.5 million, a 46% decrease from $6.6 million in 2024. This drop was primarily attributed to reduced grant income, as the company has not yet generated revenue from product sales. Operating expenses also decreased by 7% to $16.4 million, down from $17.7 million in the previous year, largely due to a reduction in clinical trial expenses. However, the company still reported a net loss of $12.2 million, compared to a loss of $10.7 million in 2024, indicating ongoing financial challenges.
In terms of strategic developments, Marker Therapeutics has made notable progress in its clinical programs. The company is advancing two product candidates, MT-601 and MT-401-OTS, targeting various hematological malignancies and solid tumors. The Phase 1 APOLLO study for MT-601, which focuses on patients with relapsed lymphoma, has shown promising results, with 66% of patients achieving objective responses. Additionally, the company has initiated the Off-the-Shelf (OTS) program for MT-401, which aims to provide rapid treatment options for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
Operationally, Marker Therapeutics has been working to enhance its manufacturing capabilities. The company entered into a Statement of Work with Cellipont Bioservices for the manufacturing of MT-601, aiming to scale up production for its clinical trials. As of December 31, 2025, the company had a working capital of $16.8 million, a decrease from $18.6 million in 2024, and anticipates that it can fund operations through the fourth quarter of 2026, assuming no additional grant funds are received. The company is also exploring additional capital-raising opportunities to support its ongoing research and development efforts.
Looking ahead, Marker Therapeutics faces several risks and uncertainties, including the need for substantial additional funding to continue its operations and the potential for delays in clinical trials due to regulatory requirements or other unforeseen circumstances. The company has expressed concerns about its ability to continue as a going concern, given its history of operating losses and reliance on grant funding. Despite these challenges, Marker Therapeutics remains focused on advancing its clinical programs and exploring strategic partnerships to enhance its market position in the competitive biotechnology landscape.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing non-engineered T cell therapies targeting multiple tumor antigens. Its proprietary MAR-T platform aims to treat hematological malignancies and solid tumors by expanding natural tumor-specific T cells, minimizing tumor escape and adverse effects. The company’s products include autologous and off-the-shelf therapies, with a focus on lymphoma, pancreatic cancer, AML, and MDS, leveraging broad-spectrum, cost-effective immunotherapies.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.